Evidence map›Paper›PMID 34459213›Full record

Trial reportCirculation2021

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.

Milton Packer, Javed Butler, Faiez Zannad, Gerasimos Filippatos, Joao Pedro Ferreira, Stuart J Pocock, Peter Carson, Inder Anand, Wolfram Doehner, Markus Haass and 8 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03057977. Cited by 181 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
181citing papers in PubMed, 10 pooled it
41.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03057977 phase3completed

A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

Ran2017Enrolled3,730Registered outcomes10Posted comparisons10ConditionsHeart FailureArmsempagliflozin, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

181 citing papers in PubMed, 10 syntheses or guidelines pooled it, 335 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

121 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 14 institutions in 7 countries.

Milton PackerBaylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.).ORCID 0000-0003-1828-2387
Javed ButlerDepartment of Medicine, University of Mississippi School of Medicine, Jackson (J.B.).
Faiez ZannadUniversité de Lorraine, Inserm INI-CRCT, CHRU, Nancy, France (F.Z., J.P.F.).
Gerasimos FilippatosNational and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Greece (G.F.).
Joao Pedro FerreiraUniversité de Lorraine, Inserm INI-CRCT, CHRU, Nancy, France (F.Z., J.P.F.).
Stuart J PocockDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, United Kingdom (S.J.P.).
Peter CarsonWashington DC Veterans Affairs Medical Center (P.C.).
Inder AnandDepartment of Cardiology, University of Minnesota, Minneapolis (I.A.).
Wolfram DoehnerDepartment of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany (W.D., S.D.A.).
Markus HaassTheresienkrankenhaus and St Hedwig-Klinik, Mannheim, Germany (M.H.).
Michel KomajdaDepartment of Cardiology, Hospital Saint Joseph, Paris, France (M.K.).ORCID 0000-0002-3010-5589
Alan MillerUniversity of Florida, Jacksonville (A.M.).ORCID 0000-0003-3504-6239
Steen PehrsonDepartment of Cardiology, University Hospital, Rigshospitalet, Copenhagen, Denmark (S.P.).
John R TeerlinkSection of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California (J.R.T.).
Sven SchnaidtBiostatistics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (S.S., C.Z.).
Cordula ZellerBiostatistics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (S.S., C.Z.).
Janet M SchneeBoehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT (J.M.S.).
Stefan D AnkerDepartment of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany (W.D., S.D.A.).
Boehringer Ingelheim (Germany) · DEGerman Centre for Cardiovascular Research · DEInserm · FRBaylor University Medical Center · USCopenhagen University Hospital · DKHôpital Paris Saint-Joseph · FRNational and Kapodistrian University of Athens · GRSan Francisco VA Medical Center · USSt. Hedwig-Krankenhaus · DEUniversity of Florida · USUniversity of London · GBUniversity of Minnesota · USUniversity of Mississippi Medical Center · USVeterans Health Administration · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEmpagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction, but additional data are needed about its effect on inpatient and outpatient heart failure events.

methodsWe randomly assigned 5988 patients with class II through IV heart failure with an ejection fraction of >40% to double-blind treatment with placebo or empagliflozin (10 mg once daily), in addition to usual therapy, for a median of 26 months. We prospectively collected information on inpatient and outpatient events reflecting worsening heart failure and prespecified their analysis in individual and composite end points.

resultsEmpagliflozin reduced the combined risk of cardiovascular death, hospitalization for heart failure, or an emergency or urgent heart failure visit requiring intravenous treatment (432 versus 546 patients [empagliflozin versus placebo, respectively]; hazard ratio, 0.77 [95% CI, 0.67-0.87];

conclusionsIn patients with heart failure with preserved ejection fraction, empagliflozin produced a meaningful, early, and sustained reduction in the risk and severity of a broad range of inpatient and outpatient worsening heart failure events. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03057977.

Indexed as

Benzhydryl CompoundsGlucosidesHeart FailureHumansSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitorsheart failuresodium-glucose transporter 2 inhibitors

Identifiers

PMID34459213
PMCPMC8522627
OpenAlexW3198485697

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.